Noble Financial reissued their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research report sent to investors on Tuesday.

Other equities research analysts also recently issued reports about the company. Zacks Investment Research downgraded Anavex Life Sciences from a buy rating to a hold rating in a research report on Friday, August 18th. ValuEngine downgraded Anavex Life Sciences from a hold rating to a sell rating in a research report on Thursday, September 28th. Finally, Maxim Group set a $15.00 price target on Anavex Life Sciences and gave the stock a buy rating in a research report on Thursday, October 12th.

Anavex Life Sciences (NASDAQ:AVXL) opened at $3.21 on Tuesday. Anavex Life Sciences has a 12-month low of $3.01 and a 12-month high of $6.64.

Anavex Life Sciences (NASDAQ:AVXL) last released its earnings results on Monday, December 11th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02). equities analysts forecast that Anavex Life Sciences will post -0.44 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the business. SNS Financial Group LLC acquired a new stake in Anavex Life Sciences during the 3rd quarter worth about $290,000. Northern Trust Corp grew its position in Anavex Life Sciences by 16.0% during the 2nd quarter. Northern Trust Corp now owns 429,073 shares of the biotechnology company’s stock worth $2,282,000 after purchasing an additional 59,069 shares during the period. Vanguard Group Inc. grew its position in Anavex Life Sciences by 13.1% during the 1st quarter. Vanguard Group Inc. now owns 1,485,681 shares of the biotechnology company’s stock worth $8,528,000 after purchasing an additional 171,577 shares during the period. Virtu KCG Holdings LLC acquired a new stake in Anavex Life Sciences during the 2nd quarter worth about $186,000. Finally, Geode Capital Management LLC grew its position in Anavex Life Sciences by 16.8% during the 1st quarter. Geode Capital Management LLC now owns 276,974 shares of the biotechnology company’s stock worth $1,589,000 after purchasing an additional 39,934 shares during the period. 23.88% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.watchlistnews.com/anavex-life-sciences-avxl-earns-buy-rating-from-noble-financial/1765063.html.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.